daftar pustaka acharya, b., shirakawa, t., pungky, a., damanik

DAFTAR PUSTAKA

Acharya, B., Shirakawa, T., Pungky, A., Damanik,M. P.,Massi, M. N.,Miyata, M., et al.,2005.Polymorphism of the interleukin 4, Interleukin 13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome.Am J Nephrol.25,30-5.

Abbate,M., Zoja,C., Corna,D., Capitanio,M., Bertani,T., Remuzzi,G.,1998. In progressive nephropathis, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into celluler signals of interstitial inflammation. J Am Soc Nephrol.9,1213-24.

Abbate,M.,Zoja,C.,Remuzzi,G.,2006. How does proteinuria cause progressive renal damage? J Am Soc Nephrol.17,2974-84.

Aeberli, D., Leech, M., and Morand, E., 2006a.Macrophage migration inhibitory factor and glucocorticoid sensitivity.Rheumatology.45,937-43.

Aeberli, D., Yang, Y., Mansell, A., Santos, L., Leech, M., and Morand,E.F., 2006b. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p-38 MAP kinase.FEBS.580,974-81.

Arenberg, D. and Bucala, R., 2003.Macrophage migration inhibitory factor (MIF). In: A.W.Thomson, M.T.Lotze, eds.The Cytokine Handbook. 4th

Atlas, S.A., 2007. The renin-angiotensin aldosteron system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm.13(8),S9-20.

ed.London: Elsevier Science.pp.1037-49.

Bagga, A., and Mantan, M., 2005. Nephrotic syndrome in children.Indian J Med Res.122,13-28.

Barnes,P.J., and Adcock,I.M., 2009.Glucocorticoid resistance in inflamatory diseases.Lancet.373,1905-17.

Barnes,P.J.,2011. Glucocorticoids: current and future directions. Br J Pharmacol.163,111-33.

Berdeli, A., Mir, S., Ozkayin, N., Serdaroglu, E., Tabel, Y., and Cura, A., 2005. Association of macrophage migration inhibitory factor -173 C allele polymorphism with steroid resistance in children with nephrotic syndrome.Pediatr Nephrol.20,1566-71.

Universitas Sumatera Utara

Biyikli, N., Alpay.H, Yildiz, N., Agachan, B., and Ergen, A.,2006. Paraoxonase 1 192 and 55 polymorphisms in nephrotic children. Pediatr Nephrol. 21, 649-54.

Brenner,B.M.,Lawler,E.V., and Mackenzie,H.S.,1996. The hyperfiltration theory:a paradigm shift in nephrology. Stategies for interrupting progressive renal disease.Kidney Int.49,1774-7.

Bruchfeld, A., Carrero, J., Qureshi, A., Lindholm, B., Heimburger, O., Hu, M., et al., 2009. Elevated serum macrophage migration inhibitory factor (MIF) concentration in chronic kidney disease are associated with markers of oxidative stress and endothelial activation.Mol Med.15,70-5.

Bruschi, M., Catarsi, P., Candiano, G., and Rastaldi, M.P., 2003.Apolipoprotein A in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.Kidney Int.63,686-95.

Busche, S., Gallinat, S., Fleegal, M.A., Raizada, M.K., Sumners, C., 2001. Novel role of macrophage migration inhibitory factor in angiotensin II regulation of neuromodulation in rat brain.Endocrinol.142,4623-30.

Calandra, T.,and Roger,T.,2003.Macrophage migration inhibitory factor: a regulator of innate immunity.Nat Rev Immunol.3,1038-48.

Calbreath,D.F.,1992.Clinical Chemistry: A Fundamental Textbook. Philadelphia: W.B.Saunders Company.

Camici,M.,2007. Nephrotic proteinuria and the autonomic nervous system.Saudi J Kidney Dis Transplant.18(4),512-22.

Carey, R.M., and Siragy, H.M., 2003. Newly recognized components of the renin angiotensin system: potential roles in cardiovascular and renal regulation.Endocrine Rev.24(3),261-71.

Carvalho, P., Franco, P., Elias, L., Facincani, L., Laurenco, E., and Foss, N., 2004. Glucocorticoid receptors, in vitro steroid sensitivity, and cytocine secretion in idiopathic nephrotic syndrome.Kidney Int.65,403-8.

Che,R.,Zhang,A.,2013.Mechanism of glucocorticoid resistance in idiopathic nephrotic syndrome.Kidney Blood Press Res.,37:360-78.

Cho, H.Y., Choi, H.J., Lee, S.H., Lee, H.K., Kang, H.K., Ha, I.S., et al., 2009. Polymorphisms of the NR3CI gene in Korean children with nephrotic syndrome.Korean J Pediatrics.52,1260-6.


Cvetkovic,I., and Stosic-Grujicic,S.,2006. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflamatory disorders.Int Immunopharmacol.6,1527-34.

Daun, J., and Cannon, J.,2000. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkB.Am J Physiol Reg Integrative Comp Pysiol.279,R1043-9.

De Benedetti, F., Meazza, C., Vivarelli, M., Rossi, F., Pistorio, A., Lamb, R., et al., 2003.Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic onset juvenile idiopathic arthritis.Arthritis Rheum.48(5),1398 - 407.

Denton, K.M., Anderson, W.P.,and Sinniah R.,2000. Effect of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am J Physiol Regulatory Integrative Comp Physiol.279, R629-38.

DiBona,G.F.,2001.Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves control of renal function.Am N Y Acad Sci.940,395-406.

Dios,A., Mitchell,R.A., Aljabari,B., Lubetsky,J., O’Connor,K., Liao,H.,et al., 2002. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem.45,2410-16.

Djau,V.J., Antman,E.M., Black,H.R., Hayes,D.L., Manson,J.E., Plutzky,J., et al., 2006. The cardiovascular disease continuum validated:clinical evidence of improved patient outcomes.Circulation.114,2850-70.

Don,B.R.,Biglieri,E.G.,Schambelan,M.,1997. Endocrine hypertension. In: F.S.Greenspan, G.J.Strewler,eds. Basic & Clinical Endocrinology. 5th

Donadelli,R.,Abbate,M.,Zanchi,C.,Corna,D.,Tomasoni,S.,Benigni,A.,etal., 2000. Protein traffic activates NF-kappaB gene signaling and promotes MCP-1-dependent interstitial inflammation.Am J Kidney Dis.36,1226-41.

ed. Stanford:Appleton& Lange, pp.359-80.

Donn, R., Alourfi, Z., De Benedetti, F., Meazza, C., Zeggini, E., Lunt, M., et al., 2002.Mutation screening if the macrophage migration inhibitory factor gene.Arthritis & Rheumatism.46,2402-9.

Donnely,S.C.,and Bucala.,1997.Macrophage pigration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflamatory disease.Mol Med.502-7.


Eddy,A.A, and Symons,J.,2003. Nephrotic syndrome in childhood. Lancet 362,629-39.

Eddy,A.A.,2004. Proteinuria and interstitial injury. Nephrol Dial Transplant. 19,277-81.

Elly,V., Fakhoury,M., Deschenes,G., Jacqz-Aigrain,E., 2012. Physiopathology of idioptahic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.Pediatr Nephrol.27,1249-56.

Ferguson,A.V., Washburn,D.L.S., and Latchford,K.J.,2001. Hormonal and neurotransmitter roles for angiotensin in the regulation of central autonomic function.Exp Biol Med.226,85-96.

Flaster,H., Bernhagen,J., Calandra, T., and Bucala, R.,2007. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflamation and immunity.Mol Endocrinol.21,1267-80.

Fogo,A.B.,2006. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant.21,281-4.

Funaki, S., Takahashi, S., Wada, N., Murakami, H., Harada, K., 2008. Multiple drug resistant gene 1 in children with steroid-sensitive nephrotic syndrome.Pediatr Int.50,159-61.

Fydryk, J., and Querfeld, U., 2002. The nephrotic syndrome-idiopathic steroid resistant nephrotic syndrome. In:P.Cochat,ed. ESPN Handbook. Switzerland:ESPN,pp.259-62.

Gasparo,M., Catt,K., Inagami,T., Wright, J., and Unger, T.,2000.International union of pharmacology.XXIII.The angiotensin II receptors.Pharmacol Rev.52,415-72.

Glassock,R.,2003. Circulating permeability factors in the nephrotic syndrome:a fresh look at an old problem.J Am Soc Nephrol.14,541-3.

Gruskin,A.B., Dabbagh, S., Fleischmann, L.E., Apostol, E.L., and Mattoo, T.K.,1999.Mechanism of hypertension in childhood diseases. In: T.M.Barratt, E.D.Avner, W.E.Harmon, eds.Pediatric Nephrology. 4th

Guyton, A.C.,1991.Text book of Medical Physiology.8

ed. Philadelphia:Lippincott Williams & Wilkins,pp.987-1005.

th

Haack,D.,Scharer,K.,and Vecsei,P.,1999. Glucocorticoid receptors in idiopathic nephrotic syndrome.Pediatr Nephrol.13,653-6.

ed.Philadelphia:WB Saunders Company.


Hammad,A., Yahia,S., Gouida,M.S., Bakr,A., El-farahaty,R.M.,2013. Low expression of glucocorticoid receptors in children with steroid-resistant nephrotic syndrome.Pediatric Nephrol.28,759-63.

Hattori,M.,Nikolic-Paterson D.J., Miyazaki K., Isbel N.M., Lan H.Y., Atkins R.C., et al.,1999.Mechanism of glomerular macrophage infiltration in lipid induced renal injury.Kidney Int. 55(71),S47-50

Haycock,G.,2003. The child with idiopathic nephrotic syndrome. In: J.A. Nicholas,R.J.Postlethwaite, eds. 2003. Clinical Paediatric Nephrology. 3rd

Herizi, A., Jover, B., Bouriquet, N., and Mimran, A.,1998. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.Hypertension.31,10-4.

ed. New York: Oxford University Press,pp.341-66.

Hildebrandt, J.D.,2007.Renin Angiotensin System (RAS). Online. Available from: http://www.slideword.org/slidestag.aspx/raas

Hogg,R.J.,Portman,R.J.,Milliner,D.,Lemley,K.V.,Eddy,A., & Ingelfinger,J., 2000. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE).Pediatrics.105,1242-9.

[Accessed 25 April 2009]

Hogg,R.J., Furth,S., Lemley,K.V., Portman,R., Schwartz,G.J., Coresh,J., et al., 2003. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical practice guidelines for chronic kidney disease in children and adolescents:evaluation,classification and stratification. Pediatrics.111,1416-21.

Huang,Z.,Wen,Q.,Zhou,S.,Yu,X.,2008.Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome.Cytokine.42,222-33.

Hubner,N., Kreutz,R., Takahashi,S., Ganten,D., Lindpaintner,K., 1995. Altered angiotensinogen amino acid sequence and plasma angiotensin II levels in genetically hypertensive rats. A study of cause and effect. Hypertension,26(2),279-84.

Hurairah, H.,Ferro, A.,2004. The role of the endothelium in the control of vascular function.J Clin Pract.58,173-83.


Ingelfinger,J.R.,2004. Monogenic and polygenic genetic contributions to hypertension. In: R.J.Portman, J.M.Sorof, J.R.Ingelfinger, eds.Clinical Hypertension and Vascular disease: Pediatric Hypertension.New Jersey: Humana Press Inc.,pp.225-38.

ISKDC.,1978. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristic at time of diagnostic.Kidney Int.13,159-65.

ISKDC.,1981. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone.J Pediatr.98,561-4.

Ito,K.,Chung,F.,and Adcock,I.M.,2006. Update on glucocorticoid action and resistance.J Allergy Clin Immunol.117,522-43.

Iuchi,T., Akaike,M., Mitsui,T., Ohshima,Y., Shintani,Y., Azuma,H., et al., 2003. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction.Circ Res.92,81-7.

Jalanko,H.,2003. Pathogenesis of proteinuria: lesson learned from nephrin and podocin.Pediatr Nephrol.18,487-91.

Jan, M., Markus, J., Bernd, H., Querfeld, U., Dirk, E., Grant, M., et al., 2008. The clinical course of steroid sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism.Nephrol Dial Transplant.23,3841-4.

Kaplan,N.M.,2006.Clinical Hypertension.9th

Kim, S., Kim, I., Lee, B., Choi, K., Chung, J., Ihm, C., et al.,2003. Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome. Pediatr Nephrol.18, 230-3.

ed.Taunton:Lippincott Williams & Wilkins

Kleemann,R.,Kapurniotu,A.,Frank,R.W.,Gessner,A.,Mischke,R.,Flieger,O.,et al., 1998. Disulfide analysis reveals a role for macrophage migration inhibitory factor as thiol-protein oxidoreductase.J Mol Biol.280,85-102.

Kleinbaum,D.G and Klein,M.,2002. Statistics for Biology and Health. Logistic Regression: A Self Learning Text. 2nd

Kumagai,H., Onami,T., Iigaya,K., Takimoto,C., Imai,M., Matsuura,T., et al., 2004. Involvement of renal sympathetic nerve in pahogenesis of

ed. New York: Springer Science


hypertension. In: H.Suzuki,T.Saruta,eds.Kidney and Blood Pressure Regulation.Basel:Karger, vol.143,pp.32-45.

Lan, H.Y.,2008. Role of macrophage migration inhibition factor in kidney disease.Nephron Exp Nephrol.109,e79-83.

Langham,R.G.,Kelly,D.J.,Cox,A.J.,Gow,R.M.,Holthofer,H.,Gilbert,R.,2004.Angiotensin II induces proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant.19(1),262-3

Leng, L., Metz, C., Fang, Y., Xu, J., Donnelly, S., Baugh, J.,et al.,2003. MIF signal transduction initiated by binding to CD 74.J Exp Med.197(11), 1467-76.

Leng,L., Wang,W., Roger,T., Merk,M., Wuttke,M., Calandra,T., et al.,2009. Glucocorticoid induced MIF expression by human CEM T cells. Cytokine.48,177-85.

Lewin, B.,2000. Genes VII. 1st

Lewis,C.M., and Knight,J.,2012. Introduction to genetic association studies.Cold Spring Harb Protoc.,doi:10.1101/pdb.top068163.

ed. Massachussets. Oxford University Press

Liao, T., Yang, X., Liu, Y., Shesely, E., Cavasin, M., Kuziel, W., et al., 2008. Role of inflamation in the development of renal damage and dysfunction in angiotensin II induced hypertension.Hypertension.52,256-63.

Lue, H., Kleemann, R., Calandra, T., Roger, T., and Bernhagen,J.,2002. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease.Microbes and Infection.4,449-60.

Madiyono, B., Moeslichan, M., Sastroasmoro, S., Budiman, I., and Harry, P., 2002. Perkiraan besar sampel. In: S.Sastroasmoro , S. Ismael, eds. 2002. Dasar-dasar metodologi penelitian klinis. 2nd

Mathieson,P.W.,2003. Immune dysregulation in minimal change nephropathy. Nephrol Dial Transplant.18,26-9.

ed. Jakarta: Sagung Seto,pp.259-86.

McKinney,P.A., Feltbower,R.G., and Brocklebank, J.T.,2001. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol.16,1040-4.

Meer,V.D.,Cravedi,P., and Remuzzi,G.,2010. The role of renin angiotensin system inhibition in kidney repair.Fibrogen & Tissue Repair.1-11.


Mehls,O.,and Hoyer,P.F.,2011. Dosing glucocorticoids in nephrotic syndrome. Pediatr Nephrol.26,2095-8.

Miller,P.L., Rennke,H.G., and Meyer,T.W.,1991. Glomerular hypertrophy accelerates hypertensive glomerular injury in rats.Am J Physiol. 261,F459-65.

Mitch,W.E.,1997. Influences of diet on the progression of chronic renal insufficiency. In: J.D.Kopple, S.G.Massry,eds. Nutritional Management of Renal Disease. Baltimore:William&Wilkins,pp.317-40.

Morand,E.F,2005. New therapeutic target in inflamatory disease: macrophage migration inhibitory factor.Intern Med J.35,419-26.

Morand,E.F.,Leech,M.,and Bernhagen,J.,2006.MIF: new cytokine link between rheumatoid arthritis and atherosclerosis.Nature Rev Drug Discov.10,1-10.

Murea,M., Register,T.C., Divers, J., Bowden, D.W., Carr, J.J., Hightower, C.R.,et al.,2012. Relationship between serum MCP-1 and subclinical kidney disease.BMC Nephrol.13,148-64.

National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion, 2000. Growth charts for the United States: methods and development. Available from: http://www.cdc.gov/growthcharts

Navar, L. and Hamm, L.,1999. The kidney in blood pressure regulation. In: Schrier R.W.,ed. Atlas of disease of the kidney. Denver: University of Colorado School of Medicine, pp.1.1-22.

Neild,G.,2009. What do we know about chronic renal failure in young adults? II. adult outcome of pediatric renal disease.Pediatr Nephrol.24,1921-8.

NHBPEP.,2004. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescent.Pediatrics,114,555-76.

Niaudet,P.,1993. Nephrotic syndrome in children.Cur Opin Pediatr.5,174-9.

Niaudet, P.,1999. Steroid resistant idiopathic nephrotic syndrome.In: T.M.Barrat, E.D.Avner, and W.E.Harmon,eds.1999. Pediatric Nephrology.4th

Niaudet,P.,2004. Steroid resistant idiopathic nephrotic syndrome in children. In: E.D.Avner, W.E.Harmon, P.Niaudet, eds.Pediatric Nephrology. 5

ed.Baltimore: Lippincott Williams & Wilkins,pp.749-63.

thed.Philadelphia:Lippincott Williams & Wilkins,pp.557-73.


http://www.cdc.gov/growthcharts�

Oppenheim,J.J., Ruscetti,F.W., and Faltynek,C., 2001. Cytokines.In: D.P.Stites, A.I.Terr,T.G.Parslow,eds. Basic & Clinical Immunology.8th

Otukesh,H., Otukesh,S., Mojahedzadeh,M.,Hoseini,R., Fareshtehnejad, S.M., and Fard, A., 2009. Management and outcome of steroid resistant nephrotic syndrome in children.Iran J Kidney Dis.3,210-7.

ed. Connecticut: Appleton & Lange.pp.105-23.

Pagano,M., and Gauvreau,K.,2000. Principles of Biostatistics. 2nd

Pan,J.H.,Sukhova,G.K.,Yang,J.T.,Wang,B.,Xie,T.,Fu,H.,etal.,2004. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice.Circulation.109,3149-53.

ed. Boston:Duxbury Thomson Learning.

Paradis,P.,Schiffrin,E.L.,2009.Renin angiotensin aldosteron and pathobiology of hypertension.In:W.C.Demello, and E.D.Frohlich,eds.Renin Angiotensin System and Cardiovascular disease.New Jersey:Humana Press,pp.35-57.

Partini, P.T.,2007 Kadar Transforming Growth Factor Beta-1 (TGF-β1) urin pada berbagai keadaan proteinuria dan efek penambahan losartan pada lisinopril terhadap kadar TGF-β1 urin pada anak dengan sindrom nefrotik resisten steroid: suatu uji klinis acak terkontrol. Disertasi. Jakarta, Indonesia: FK UI.

Petrovsky, N., Socha, L., Silva, D., Grossman, A., Metz, C. and Bucala, R., 2003. Macrophage migration inhibitory factor exhibits a pronounced circadian rhytm relevant to its role as a glucocorticoid counter regulator. Immunol.& Cell Biol.81,137-43.

Philo,J.S.,Yang,T.H.,LaBarre M.,2004.Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution.Biophys Chem.108,77-87.

Pujols,L.,Mullol,J.,Roca-Ferrer,J.,Torrego,A.,Xaubet,A.,Cidlowski,J.A.,Picado, C 2002. Expression of glucocorticoid receptor α and β-isoforms in human cells and tissues.Am J Physiol Cell Physiol.283,C1324-31.

Raij,L.,2001.Hypertension and cardiovascular risk factor: role of the angiotensin II- nitric oxide interaction.Hypertension.37,767-73.

Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B., Griendling, K., et al.,1996.Angiotensin II mediated hypertension in the rat increases


vascular superoxide production via membrane NADH/NADPH oxidase activation.The Journal of Clin Invest.97,1916-23.

Read,A and Donnai,D.,2007. New Clinical Genetics. Oxfordshire:Scion Publishing Ltd.

Reidy, K., and Kaskel, F.,2007. Pathophysiology of focal segmental glomerulosclerosis.Pediatr Nephrol.22,350-4.

Rice, E.K., Tesch, G.H., Cao, Z., Cooper, M.E., Metz, C.N., Bucala, R., et al., 2003. Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II.Kidney Int.63,1265-75.

Rosengren,E., Bucala,R., Aman,P., Jacobsson.L., Odh,G., et al., 1996. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction.Mol Med.2(1),143-9.

Ruiz-Ortega,M., Lorenzo,O., Ruperez,M., Blanco,J., Eqido,J., 2001. Systemic infusion of angiotensin II into normal rats activates nuclear factor kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors.Am J Pathol.158(5),1743-56.

Ruster, C. and Wolf, G.,2006. Renin-angiotensin-aldosteron system and progression of renal disease.J Am Soc Nephrol.17,2985-91.

Sanchez-Palacios,M.,Jones,S.Y.,and DiBona,G.F.,1998. Role of angiotensin in renal sympathetic activation in nephrotic syndrome.Am J Physiol Regulatory Integrative Comp Physiol.274,808-13.

Sasaki,S.,Nishihira,J.,Ishibashi,T.,Yamasaki,Y.,Obikane,K.,Echigoya,M.,et al., 2004. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney.Kidney Int.65,469-81.

Sasongko, T., Sadewa, A., Kusuma, P., Damanik, M., Lee, M. J., Ayaki, H., et al.,2005. ACE gene polymorphism in children with nephrotic syndrome in Indonesian population.Kobe J Med Sci.51,41-7.

Savin, V. J., Sharma, R., Sharma, M., McCarthy, E. T., Swan, S. K., Ellis, E., et al.,1996.Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med.334,878-83.

Sayeski, P., and Bernstein, K., 2001. Signal transduction mechanism of the angiotensin II type AT1-receptor: looking beyond the heterotrimeric G protein paradigm.JRAAS.2,4-10.


Schneider,E. and Dy,M.,1985.Activation of macrophages.Comp Immune Microbial Infect Dis.135-46.

Schwartz, G.J., Haycock, G.B., Edelmann, C.M.Jr., Spitzer,A.,1976. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.Pediatrics.58,259-63.

Shastry,B.S.,2007.SNPs in disease gene mapping, medicinal drug development and evolution.J Hum Genet.52,871-80.

Stachowski, J.,Zanker, C.,Runowski, D.,Zaniew, M.,Peszko, A., and Medynska, A.,2000.Resistance to therapy in primary nephrotic syndrome: effect of MDR gene activity.Pol Merkur Lekarski.8,218-21.

Stenvinkel, P.,Heimburger, O.,Paultre, F.,Diczfalusy, U.,Wang, T.,Berglund, L.,et al.,1999. Strong association between malnutrition, inflamation, and atherosclerosis in chronic renal failure.Kidney Int.55,1899-911.

Stoppe,C.,Bernhagen,J.and Rex,S.,2013.Macrophage migration inhibitory factor in critical illness:Dr.Jekyll and Mr.Hyde.In: J.L.Vincent,ed.Annual Update in Intensive Care and Emergency Medicine.Berlin:Springer-Verlag Heidelberg.pp.153-61.

Stosic, S.G.,Stojanovic, I. and Nicoletti, F.,2009.MIF in autoimmunity and novel therapeutic approaches.Autoimmunity Rev.8,244-9.

Subowo,S.,2009. Imunobiologi. 2nd

Sun, C., Li, H., Leng, L., Raizada, M. K., Bucala, R., and Sumners, C., 2004. Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity.J Neurosci. 24(44),9944-52.

ed. Jakarta: Sagung Seto

Taal, M.W.,and Brenner,B.M.,2000.Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonist.Kidney Int.57,1803-17.

Taal,M.W., Lucyckx,V.A., and Brenner,B.M., 2003.Adaptation to nephron loss. In:B.M.Brenner, F.C.Rector, eds. Brenner & Rector’s The Kidney.7th

Takase,O.,Hirahashi,J.,Takayanagi,A.,Chikaraishi,A.,Marumo,T.,Ozawa,Y.,et al.,2003. Gene transfer of truncated IkappaB prevents tubulointerstitisial injury.Kidney Int.63,501-13.

ed. Philadelphia:WB Saunders,pp.1955-83.


Takenaka,T.,Hayashi,K.,and Ikenaga,H., 2004. Blood pressure regulation and renal microcirculation. In: H.Suzuki, T.Saruta, eds.Kidney and Blood Pressure Regulation.Basel:Karger,vol.143,pp.46-64.

Textor, S.C.,1999. Renal parenchymal disease and hypertension. In: Schrier R.W.,ed. Atlas of disease of the kidney. Denver: University of Colorado School of Medicine,pp.2.1-15.

Tharaux, P.,Chatziantoniou, C.,Fakhouri, F.,and Dussaule, J.,2000. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway.Hypertension.36,330-6.

The ESCAPE Trial Group, 2009. Strict blood pressure control and progression of renal failure in children.N Engl J Med.361(17),1639-50.

Towers,R.,Naftali,T.,Gabay,G.,Carlebach,M., Klein,A. and Novis,R., 2005. High levels of glucocorticoid receptors in patients with active Chrohn's disease may predict steroid resistance.Clin and Experiment Imunol. 141,357-62.

Tripathi, G.,Jafar, T.,Mahdi, A., Awasthi, S., Sharma, R., Kumar, A., et al., 2008. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome?Indian J Med Sci.62,383-91.

Tsikouris, J., and Cox, C., 2003. Pharmacologic blockade of the renin angiotensin system: vascular benefits beyond commonly understood pharmacologic action. Pharmacotherapy.23(9),19-22.

UKK, Nefrologi. 2008. Konsensus tata laksana sindrom nefrotik idiopatik pada anak.Jakarta:Badan Penerbit IDAI.

Undang-undang RI.,2002. Undang-undang Republik Indonesia No 23 tahun 2002 tentang perlindungan anak. Online. Available from: http://www.mastel.or.id/files

Undang-undang RI.,2009. Undang-undang Republik Indonesia No 36 tahun 2009 tentang kesehatan. Online. Available from:

[Accessed 1 Juni 2011]

http://www.digilib.ampl.net

Van Kats,J., Schalekamp,M., Verdouw,P., Duncker, D., and Jan Danser, A.,2001. Intrarenal angiotensin II: interstitial and cellular levels and site of production.Kidney Int. 60,2311-7.

[Accessed 1 Juni 2011]

van Rossum, E.F., and Lamberts, S.W., 2006.Glucocorticoid resistance syndrome a diagnostic and therapeutic approach.Best Pract Res Clin Endocrinol & Metab.20,611-26.


Vianna,H.R., Soares,C.M.B., Silviera,K.D., Elmiro,G.S., Mendes,P.M., et al., 2012. Cytokine in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases. Pediatr Nephrol. DOI 10.1007/s00467-012-2363-x

Victor,X.V.,2005. Angiotensin II mediated regulation of the human angiotensin II type 1 receptor gene.Disertasi. Brigham Young University, England.

Vivarelli, M., D'Urbano, L.E., Stringini, G., Ghiggeri, G.M., and Caridi, G., 2008. Association of macrophage migration inhibitory factor -173C allele with childhood nephrotic syndrome.Pediatr Nephrol.23,743-8.

Volpe,M.,2008. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice.Int J Clin Pract.62(1),97-108

Vogt, A., and Avner, E.,2007. Nephrotic syndrome. In Behrman, R.M., Kliegman, R.M. & Jenson H.B. (Eds.).Nelson Textbook of Pediatrics.18th

Vollard H., Pradelles Ph., Ronco P., Azizi M., Simon D., Creminon C., Grassi J.,1999. A solid-phase immobilized epitope immunoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma. J Immunol Methods.228,37-47.

ed. Philadelphia: WB Saunders, pp.2190-5.

Walach,H.,Falkenberg,T.,Fonnebo,V.,Lewith,G.,Jonas,W.B.,2006. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions.BMC Medical Research Method.6,29.

Wei, C.L., Cheung, W., Chew-Kiat, Arty, N., Chong, S.S., Lee, B.W., et al.,2005. Interleukin 13 genetic polymorphisms in Singapore Chinese children correlate with long term outcome of minimal-change disease. Nephrol Dial Tansplant.20,728-34.

Wikstrom, A.C.,2003. Mechanism of steroid action and resistance in inflamation. Glucocorticoid action and novel mechanism of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness. J Endocrinol.178,331-7.

Wila Wirya,I.,1992. Penelitian beberapa aspek klinis dan patologi anatomis sindrom nefrotik primer pada anak di Indonesia. Disertasi. Jakarta, Indonesia:FK UI.

Wolf,G.,2000. Angiotensin II as a mediator of tubulointerstitial injury.Nephrol Dial Transplant.15,61-3.


Wolf,G., Butzman,U., Wenzel,U.O., 2003. The renin angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol.93,3-13.

Yan,K., Kudo,A., Hirano,H., Watanabe,T., Tasaka,T., Kataoka,S., et al.,1999. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus.Kidney Int.56,65-73.

Yang,N., Nikolic-Paterson,D.J., Ng,Y., Mu,W., Metz,C., Bacher,M.,et al.,1998. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF):potential role of MIF in regulating glucocorticoid production.Mol Med.4,413-24.

Yi, Z.W., and He, Q.N., 2006. Strengthening clinical research in chilhood steroid-resistant nephrotic syndrome.World J Pediatr.2,165-8.

Zandi-Nejad,K.,Eddy,A.A.,Glassock,R.J.,Brenner,B.M.,2004. Why is proteinuria an ominous biomarker of progressive kidney disease?Kidney Int. 66(92),S76-89.

Zhao,H.Y.,Sun,R.P.,Dong,J.H.,Zhen,J.H.,2005. Relations of nuclear factor-kappa B activity in the kidney of children with primary nephrotic syndrome to clinical manifestations, pathological types and urinary protein excretion.Chin Med J.118(10),54-6.

Zeisber,M., Maeshima,Y., Mosterman,B., Kalluri,R., 2002. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cell.Am J Pathol.160,2001-8.


daftar pustaka acharya, b., shirakawa, t., pungky, a., damanik

Documents